About palisade bio - PALI
Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. It offers LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. The company was founded on September 6, 2011 and is headquartered in Carlsbad, CA.
PALI At a Glance
Palisade Bio, Inc.
7750 El Camino Real
Carlsbad, California 92009
| Phone | 1-858-704-4900 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -14,438,000.00 | |
| Sector | Health Technology | Employees | 8 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
PALI Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.264 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.492 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.023 |
PALI Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,804,750.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
PALI Liquidity
| Current Ratio | 3.22 |
| Quick Ratio | 3.22 |
| Cash Ratio | 3.035 |
PALI Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -115.819 |
| Return on Equity | -153.555 |
| Return on Total Capital | -188.461 |
| Return on Invested Capital | -152.823 |
PALI Capital Structure
| Total Debt to Total Equity | 2.256 |
| Total Debt to Total Capital | 2.206 |
| Total Debt to Total Assets | 1.553 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |